Kate Cwynarski
@cwynkate2.bsky.social
Lymphoma & partic CNSL, TCL & immunodeficiency
UCLH/UCL (no medical advice)
views my own
UCLH/UCL (no medical advice)
views my own
Reposted by Kate Cwynarski
Going to ASCO this weekend? Come say hi to our team Ann LaCasce, Nina Shah , David Wright & see our global Gender Equity Survey results.
Poster board 396, June 1st, 9-12pm
More details about the survey to come at our EHA presentation June 14th, 5:15pm in Amber Hall 3+4
Poster board 396, June 1st, 9-12pm
More details about the survey to come at our EHA presentation June 14th, 5:15pm in Amber Hall 3+4
May 28, 2025 at 10:06 AM
Going to ASCO this weekend? Come say hi to our team Ann LaCasce, Nina Shah , David Wright & see our global Gender Equity Survey results.
Poster board 396, June 1st, 9-12pm
More details about the survey to come at our EHA presentation June 14th, 5:15pm in Amber Hall 3+4
Poster board 396, June 1st, 9-12pm
More details about the survey to come at our EHA presentation June 14th, 5:15pm in Amber Hall 3+4
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Of 3,066 patients:
(2,536 B cell lymphoma, 162 ALL, 368 MM)
ONLY 1 (0.03%) pt dev a T cell malignancy after CAR T infusion
@RemyDulery
Roch Houot
@NatureMedicine
pubmed.ncbi.nlm.nih.gov/39779930/
Of 3,066 patients:
(2,536 B cell lymphoma, 162 ALL, 368 MM)
ONLY 1 (0.03%) pt dev a T cell malignancy after CAR T infusion
@RemyDulery
Roch Houot
@NatureMedicine
pubmed.ncbi.nlm.nih.gov/39779930/
T cell malignancies after CAR T cell therapy in the DESCAR-T registry - PubMed
The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompa...
pubmed.ncbi.nlm.nih.gov
January 9, 2025 at 5:25 PM
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Of 3,066 patients:
(2,536 B cell lymphoma, 162 ALL, 368 MM)
ONLY 1 (0.03%) pt dev a T cell malignancy after CAR T infusion
@RemyDulery
Roch Houot
@NatureMedicine
pubmed.ncbi.nlm.nih.gov/39779930/
Of 3,066 patients:
(2,536 B cell lymphoma, 162 ALL, 368 MM)
ONLY 1 (0.03%) pt dev a T cell malignancy after CAR T infusion
@RemyDulery
Roch Houot
@NatureMedicine
pubmed.ncbi.nlm.nih.gov/39779930/
Reposted by Kate Cwynarski
Patient-entered data in Waldenstrom’s: WhiMSICAL delivers real world outcomes and empowers patients to be partners in research. Congrats Ryan Low, @judithtrotman.bsky.social IMWF, WMozzies #ASH24 #ASHKudos
December 8, 2024 at 3:43 PM
Patient-entered data in Waldenstrom’s: WhiMSICAL delivers real world outcomes and empowers patients to be partners in research. Congrats Ryan Low, @judithtrotman.bsky.social IMWF, WMozzies #ASH24 #ASHKudos
Reposted by Kate Cwynarski
Such a beautiful energy @womeninlymphoma.bsky.social @judithtrotman.bsky.social and plans for the next WiL projects #lymsm #ASH24
December 9, 2024 at 10:41 PM
Such a beautiful energy @womeninlymphoma.bsky.social @judithtrotman.bsky.social and plans for the next WiL projects #lymsm #ASH24
Reposted by Kate Cwynarski
Reposted by Kate Cwynarski
Our multidisciplinary team identified that in #lymsm patients having anthracycline, coronary artery calcium measured on baseline PET/CT predicts cardiac events
ashpublications.org/bloodadvance... #hemesky @onjcri.bsky.social
ashpublications.org/bloodadvance... #hemesky @onjcri.bsky.social
PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated lymphoma patients
Key Points. Coronary calcium score calculated on pre-treatment PET/CT identifies lymphoma patients at risk of cardiac events after anthracycline therapyCor
ashpublications.org
November 23, 2024 at 8:40 PM
Our multidisciplinary team identified that in #lymsm patients having anthracycline, coronary artery calcium measured on baseline PET/CT predicts cardiac events
ashpublications.org/bloodadvance... #hemesky @onjcri.bsky.social
ashpublications.org/bloodadvance... #hemesky @onjcri.bsky.social
Reposted by Kate Cwynarski
Just out at JAMA Oncology, led by Parsa Erfani
We review why many efforts to improve access to oncology medicines around the world have failed so far, especially compared to infectious diseases, & offer potential strategies to improve global pharmacoequity
jamanetwork.com/journals/jam...
We review why many efforts to improve access to oncology medicines around the world have failed so far, especially compared to infectious diseases, & offer potential strategies to improve global pharmacoequity
jamanetwork.com/journals/jam...
November 16, 2024 at 2:09 AM
Just out at JAMA Oncology, led by Parsa Erfani
We review why many efforts to improve access to oncology medicines around the world have failed so far, especially compared to infectious diseases, & offer potential strategies to improve global pharmacoequity
jamanetwork.com/journals/jam...
We review why many efforts to improve access to oncology medicines around the world have failed so far, especially compared to infectious diseases, & offer potential strategies to improve global pharmacoequity
jamanetwork.com/journals/jam...
Reposted by Kate Cwynarski
🌏 Please join our free educational #CareerDevelopment webinar next Wed Nov 20 with Laurence Hollobon + panel of emerging global women in lymphoma⚕️
👉Please register us06web.zoom.us/webinar/regi...
With thanks to Gilead Sciences, IFLI, Eli Lilly & Co, Lymphoma Australia
👉Please register us06web.zoom.us/webinar/regi...
With thanks to Gilead Sciences, IFLI, Eli Lilly & Co, Lymphoma Australia
November 16, 2024 at 9:01 AM
🌏 Please join our free educational #CareerDevelopment webinar next Wed Nov 20 with Laurence Hollobon + panel of emerging global women in lymphoma⚕️
👉Please register us06web.zoom.us/webinar/regi...
With thanks to Gilead Sciences, IFLI, Eli Lilly & Co, Lymphoma Australia
👉Please register us06web.zoom.us/webinar/regi...
With thanks to Gilead Sciences, IFLI, Eli Lilly & Co, Lymphoma Australia